Alfred Scheidegger

Alfred is the visionary behind Nextech Invest Ltd’s mission, having identified the benefit of specialization and the investment opportunity in oncology. In 2006, Alfred recruited a group of world-leading oncology academics, led by David Livingston of the Dana Farber Cancer Institute, forming the core of today’s team of scientific partners, and began investing in oncology therapeutics, diagnostics and devices.

Currently, Alfred serves on the board of Dottikon ES Holding and Rising Tide Foundation. Past board representations include Ganymed Pharmaceuticals (acquired by ATS then by Takeda), Macrogenics (MGNX), Molecular MD (acquired by ICON), Tracon Therapeutics (TCON), TetraLogic Pharmaceuticals (TLOG), Agensys (acquired by Astellas).

Prior to Nextech, Alfred was managing director and member of the board of the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. He served as the first managing director of the Swiss Supercomputing Center (CSCS), after he directed an international drug-discovery project at Ciba-Geigy (today Novartis), Japan. Alfred holds a Ph.D. in microbiology and biochemistry from the University of Basel, Switzerland, and completed postdoctoral research training in enzymology at the University of Kyoto, Japan and an executive training program (TGM) at Harvard Business School, USA.